Home » News » Conference Coverage » American Society of Hematology (ASH) » ASH 2020 » ASH 2020 CLL In-depth
ASH 2020 CLL In-depth
Complete Coverage Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
LOXO-305 treatment of heavily pretreated CLL/SLL resulted in durable, high response rates in a phase 1/2 trial.
Ibrutinib was associated with a longer duration until second-line treatment, regardless of risk status, compared with CIT among patients with CLL.
The combination was also associated with improvements in progression-free and overall survival.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Load More
Open
Next post in ASH 2020 CLL In-depth
Close
Close more info about Prognostic Biomarker Testing in CLL/SLL Remains Low
Loading...
Close more info about Prognostic Biomarker Testing in CLL/SLL Remains Low
Loading...